Study protocol on Alzheimer’s disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions
Authors:
- Nawele BoublayNBNawele Boublay
- Denis FédéricoDFDenis Fédérico
- Alain PesceAPAlain Pesce
- Marc VernyMVMarc Verny
- Frédéric BlancFBFrédéric Blanc
- Marc PaccalinMPMarc Paccalin
- Thomas DesmidtTDThomas Desmidt
- Pierre GrosmaîtrePGPierre Grosmaître
- Olivier MoreaudOMOlivier Moreaud
- Solveig RellandSRSolveig Relland
- Estelle BravantEBEstelle Bravant
- Romain BouetRBRomain Bouet
Open Access
- 14 November 2018
- journal article
- research article
- Published by Springer Nature in BMC Geriatrics
- Vol. 18 (1) , 280
Abstract
One of the crucial challenges for the future of therapeutic approaches to Alzheimer’s disease (AD) is to target the main pathological processes responsible for disability and dependency. However, a progressive cognitive impairment occurring after the age of 70, the main population affected by dementia, is often related to mixed lesions of neurodegenerative and vascular origins. Whereas young patients are mostly affected by pure lesions, ageing favours the occurrence of co-lesions of AD, cerebrovascular disease (CVD) and Lewy body dementia (LBD). Most of clinical studies report on functional and clinical disabilities in patients with presumed pure pathologies. But, the weight of co-morbid processes involved in the transition from an independent functional status to disability in the elderly with co-lesions still remains to be elucidated. Neuropathological examination often performed at late stages cannot answer this question at mild or moderate stages of cognitive disorders. Brain MRI, Single Photon Emission Computed Tomography (SPECT) with DaTscan®, amyloid Positron Emission Tomography (PET) and CerebroSpinal Fluid (CSF) AD biomarkers routinely help in performing the diagnosis of underlying lesions. The combination of these measures seems to be of incremental value for the diagnosis of mixed profiles of AD, CVD and LBD. The aim is to determine the clinical, neuropsychological, neuroradiological and biological features the most predictive of cognitive, behavioral and functional impairment at 2 years in patients with co-existing lesions. A multicentre and prospective cohort study with clinical, neuro-imaging and biological markers assessment will recruit 214 patients over 70 years old with a cognitive disorder of AD, cerebrovascular and Lewy body type or with coexisting lesions of two or three of these pathologies and fulfilling the diagnostic criteria for dementia at a mild to moderate stage. Patients will be followed every 6 months (clinical, neuropsychological and imaging examination and collection of cognitive, behavioural and functional impairment) for 24 months. This study aims at identifying the best combination of markers (clinical, neuropsychological, MRI, SPECT-DaTscan®, PET and CSF) to predict disability progression in elderly patients presenting coexisting patterns. NCT02052947 .Keywords
Funding Information
- National French Program of Hospital Clinical Research (2012)
This publication has 63 references indexed in Scilit:
- Prevalence and Clinical Implication of Microbleeds in Dementia with Lewy Bodies in Comparison with Microbleeds in Alzheimer's DiseaseDementia and Geriatric Cognitive Disorders Extra, 2013
- White Matter Hyperintensities in Mild Lewy Body DementiaDementia and Geriatric Cognitive Disorders Extra, 2012
- Cerebrovascular lesions induce transient -amyloid depositionBrain, 2011
- Instrumental Activities of Daily Living Impairment Is Associated with Increased Amyloid BurdenDementia and Geriatric Cognitive Disorders, 2011
- Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAASJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Low sensitivity in clinical diagnoses of dementia with Lewy bodiesJournal of Neurology, 2009
- Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosisBrain, 2008
- Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementiaBrain, 2006
- CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek populationEuropean Journal of Neurology, 2003
- Comparison of Different Clinical Criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the Diagnosis of Vascular DementiaStroke, 2000